Danaher: Pardis Sabeti
Pardis Sabeti has notified Danaher of her retirement from the firm's board of directors as of Dec. 10 due to time commitments from her other professional obligations. Sabeti is a core institute member of the Broad Institute of MIT and Harvard and a leader in the Broad's Infectious Disease and Microbiome Program. She is also a professor at the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at Harvard University, a professor in the Department of Immunology and Infectious Disease at Harvard T.H. Chan School of Public Health, and a Howard Hughes Medical Institute investigator.
QuidelOrtho: John Chiminski, Scott Huennekens
QuidelOrtho has added John Chiminski and Scott Huennekens to its board of directors. They replace James Prutow and Robert Schmidt, who resigned from the board effective Nov. 21.
Chiminski previously served as CEO of biopharma service provider Catalent and as president and CEO of GE Medical Diagnostics. Huennekens was previously chair, president, and CEO of Verb Surgical, president and CEO at Volcano Corp. and Digirad, and he also held various leadership positions at Baxter Healthcare, Birtcher Medical Systems, and Deloitte & Touche.
National Academy of Inventors: Mark Akeson
Mark Akeson, professor emeritus at the University of California, Santa Cruz, has been named a fellow of the National Academy of Inventors. He co-invented nanopore sequencing, developing foundational technology that was licensed by Oxford Nanopore Technologies in 2008.
Myriad Genetics: Mark Davis
Myriad Genetics elected Mark Davis to its board of directors, effective immediately, expanding the board from eight to nine members. Additionally, Myriad appointed Davis to the audit and finance committee of the board. Davis currently also serves as the senior relationship and growth adviser for Cross Country Consulting.
Previously, Davis held senior roles at Deloitte & Touche, including audit partner, national managing partner of Deloitte Private Enterprises, and managing partner of the Long Island office. He also serves as a director and member of the audit committee for the board of directors of Yext and is a member of the advisory board of NYU-Winthrop Hospital, as well as of the board of trustees at Adelphi University, where he serves on the finance and investment committee as well as the audit committee.
Sapient: Mohit Jain, Jonathan Usuka
Mohit Jain, CEO and founder of multiomics biomarker discovery firm Sapient, will become the firm's CSO and continue to stay on its board. Jonathan Usuka, currently Sapient's chief business officer, will assume the CEO post. He previously held leadership positions in pharmaceutical services and analytics at Realm IDx, McKinsey, Roche, and Bristol Myers Squibb.
Hologic: Martin Madaus
Hologic has appointed Martin Madaus to a newly created position on the company's board of directors effective Dec. 6. The firm said in a filing with the US Securities and Exchange Commission that Madaus was appointed to the board when it was expanded from nine members to 10. He was also appointed to Hologic's compensation committee and its nominating and corporate governance committee. Madaus is an operating executive for the Carlyle Group, and he previously served as the chairman and CEO of Ortho Clinical Diagnostics. He also was chairman, president, and CEO of life sciences firm Millipore prior to its 2010 acquisition by Merck.
Pacific Biosciences: Susan Kim, Christian Henry
Pacific Biosciences announced in a filing with the US Securities and Exchange Commission that CFO Susan Kim resigned on Dec. 6. CEO Christian Henry will serve as interim CFO.
For additional recent executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.